Mpk1 Inhibitors
Mpk1 inhibitors constitute a distinct chemical class encompassing a range of small molecules engineered to intricately interact with and exert control over the mitogen-activated protein kinase (MAPK) enzyme known as Mpk1, also recognized as Extracellular Signal-Regulated Kinase 2 (ERK2). Operating as a pivotal player within intracellular signaling networks, Mpk1 orchestrates a multitude of essential cellular functions, including cellular growth, propagation, and differentiation. The paramount objective of these inhibitors revolves around their precise targeting of Mpk1's catalytic site or alternative regulatory domains, thus inducing a disruption in its enzymatic activity. A fundamental facet of Mpk1 inhibitors is their conception via rational drug design paradigms, meticulously tailored to procure elevated selectivity and potency in inhibiting Mpk1.
The intricate art of their synthesis is rooted in a sophisticated comprehension of Mpk1's structural attributes and functional behavior, enabling the formulation of compounds that can effectively interact with the enzyme's intricate architecture. By intercepting Mpk1's catalytic mechanisms or its communication with key cellular substrates, Mpk1 inhibitors offer a gateway to unraveling the labyrinthine pathways through which cells perceive and interpret extracellular cues. These inhibitors encapsulate the evolving knowledge surrounding Mpk1's intricate roles in physiological processes and pathological developments. Their structural diversity and synthetic versatility empower researchers to delve into the intricate nuances of Mpk1's involvement in diverse facets of cellular regulation, ultimately broadening our grasp of both normal physiological responses and aberrant disease pathways.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
SCH772984 | 942183-80-4 | sc-473205 | 5 mg | $370.00 | 5 | |
A highly specific inhibitor that directly targets ERK1/2, the downstream effectors in the MAPK pathway. By inhibiting ERK1/2, SCH772984 effectively disrupts the phosphorylation cascade essential for Mpk1 pathway signaling, blocking its activation and signaling functions. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
Primarily known for its inhibition of certain BRAF mutations, Vemurafenib also exerts its effect on the MAPK pathway by blocking BRAF kinase, an upstream regulator of MEK and ERK, which in turn inhibits the Mpk1 pathway signaling. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
This compound selectively inhibits MEK1/2, enzymes that are crucial for the phosphorylation of ERK1/2 in the MAPK pathway. By inhibiting MEK1/2, Selumetinib prevents the activation of ERK1/2 and consequently inhibits the Mpk1 signaling pathway. | ||||||
LY3214996 | 1951483-29-6 | sc-507299 | 5 mg | $265.00 | ||
Specifically designed to inhibit ERK1/2, LY3214996 directly targets and binds to ERK1/2, preventing their phosphorylation and activation. This inhibition disrupts the MAPK signaling cascade, effectively inhibiting Mpk1 pathway activity. | ||||||
TAK-733 | 1035555-63-5 | sc-364630 sc-364630A | 5 mg 10 mg | $340.00 $640.00 | 1 | |
As a MEK inhibitor, TAK-733 specifically targets and inhibits MEK1/2, preventing the downstream phosphorylation of ERK1/2. This action blocks the transmission of signals required for the activation of the Mpk1 signaling pathway. | ||||||